- Home
- LSF vs BTAI Comparison
LSF vs BTAI Comparison
Compare LSF & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | BTAI |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.8M | 49.2M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LSF | BTAI |
|---|---|---|
| Price | $2.22 | $2.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $12.00 | ★ $32.80 |
| AVG Volume (30 Days) | 112.9K | ★ 669.3K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,146,862.00 | $752,000.00 |
| Revenue This Year | $18.05 | N/A |
| Revenue Next Year | $17.53 | $544.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.73 | N/A |
| 52 Week Low | $2.25 | $1.17 |
| 52 Week High | $10.90 | $9.26 |
Technical Indicators
Market Signals| Indicator | LSF | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 25.63 | 52.36 |
| Support Level | $2.47 | $1.82 |
| Resistance Level | $2.78 | $2.33 |
| Average True Range (ATR) | 0.19 | 0.17 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 8.87 | 65.24 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.